Myriad Genetics develops and sells molecular genetic tests for cancer, prenatal health, and mental health care. It last closed at $5.46 on Nov 20, down 1.44% on the day. The next earnings report for MYGN is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, MYGN reported EPS of -$0.46 on revenue of $202.7M, with revenue down 1.5% from a year ago. Over its last 8 reports the stock moved an average of 22.5% the session after earnings. Over the last 12 months MYGN insiders bought $722K of stock on the open market and sold $101K, according to SEC Form 4 filings.
AI Auto Pilots
Is MYGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MYGN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on MYGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
MYGN · as of the Nov 20 close · updated each morning
Moving sideways
The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot at $5.45, and the nearest resistance the Pivot R1 at $5.59.
Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.0%/day
Key levels
$8.0952 week high+48.2%
$5.95Swing high (Oct 20)+9.0%
$5.9120 day average+8.2%
$5.59Pivot R1+2.4%
$5.46Last close
$5.45Pivot−0.2%
$5.32Pivot S1−2.6%
$4.9850 day average−8.8%
$4.61200 day average−15.6%
$4.60100 day average−15.8%
$4.19Swing low (Jun 15)−23.3%
$2.7452 week low−49.8%
Indicators
RSI (14)
49.15
Middle of its range
Neutral
MACD
0.13
Below its signal line
Bearish
Stochastic
9.6
Near the bottom of its range
Oversold
ADX (14)
37.0
Trending up
Williams %R
-89.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-103.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.8%
Change over 10 sessions
Bearish
ATR (14)
$0.33
Typical daily range, 6.0% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 13.8%/day
Key levels
$8.0952 week high+48.2%
$5.95Swing high (Oct 20)+9.0%
$5.9120 day average+8.2%
$5.59Pivot R1+2.4%
$5.46Last close
$5.45Pivot−0.2%
$5.32Pivot S1−2.6%
$4.9850 day average−8.8%
$4.61200 day average−15.6%
$4.60100 day average−15.8%
$4.19Swing low (Jun 15)−23.3%
$2.7452 week low−49.8%
Indicators
RSI (14)
55.44
Middle of its range
Neutral
MACD
0.23
Above its signal line
Bullish
Stochastic
72.5
Middle of its range
Neutral
ADX (14)
22.0
Weak trend
Williams %R
-33.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
62.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+59.6%
Change over 10 sessions
Bullish
ATR (14)
$0.76
Typical daily range, 13.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for MYGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MYGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow MYGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MYGNHow many large options trades hit MYGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MYGN in the last 90 days.
From SEC Form 4 filings by MYGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MYGN is in one of them and how their past MYGN trades turned out.
Myriad Genetics is a molecular diagnostics company based in Salt Lake City, Utah. It develops and sells genetic tests that help assess disease risk, guide cancer treatment, and support prenatal and mental health care. Its main areas are oncology, women's health, and mental health, with tests such as MyRisk for hereditary cancer risk and BRACAnalysis CDx for selecting cancer therapy. Its customers include doctors, healthcare providers, patients, and biopharma companies.